צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים: Y-mAbs Corp (YMAB)

Y-mAbs Therapeutics (YMAB) has developed a closed antibody delivery system for pediatric neurosurgery. Tracking the YoY revenue growth trend for TTM on GURU.Markets, we note that 113.90 represents the current level of the metric. The company maintains an impeccable reputation in the field of targeted oncology. The development of new molecules is based on AI and robotic synthesis, although final testing remains the responsibility of physicians.
Y-mAbs Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (YMAB)

This indicator measures the revenue growth rate over a rolling year, filtering out short-term market volatility to reveal the true dynamics of business scaling. Analysis of the 12-month YoY sales growth chart confirms the resilience of cash flows for Y-mAbs Therapeutics (YMAB), where patent protection for pediatric oncology drugs guarantees stable demand and transforms the asset into a reliable long-term revenue generator.